

09/736.15-1

Set Name Query
side by side**Hit Count Set Name**
result set*DB=USPT,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*

<u>L14</u>	L13 and simultaneous\$	0	<u>L14</u>
<u>L13</u>	l9 and (one step or single reaction)	17	<u>L13</u>
<u>L12</u>	L11 and simultaneous\$	0	<u>L12</u>
<u>L11</u>	L10 and (one step or single reaction)	7	<u>L11</u>
<u>L10</u>	L9 and polymerase chain reaction\$1	57	<u>L10</u>
<u>L9</u>	(fragmenting or restriction) near5 (labeling or attaching)	296	<u>L9</u>
<u>L8</u>	(fragmenting or restriction) near5 (labeling or attaching) near5 polymerase chain reaction	0	<u>L8</u>
<u>L7</u>	l4 and (one step or single reaction)	1	<u>L7</u>
<u>L6</u>	L5 and (one step or single reaction)	1	<u>L6</u>
<u>L5</u>	L4 and polymerase chain reaction\$1	1	<u>L5</u>
<u>L4</u>	fragmenting near5 labeling	8	<u>L4</u>
<u>L3</u>	fragmenting near5 labeling near5 polymerase chain reaction	0	<u>L3</u>
<u>L2</u>	L1 and (nucleic acid or DNA or RNA)	6	<u>L2</u>
<u>L1</u>	betaine near5 (elut\$ or purif\$ or extract\$)	129	<u>L1</u>

END OF SEARCH HISTORY

☐ Generate Collection

L11: Entry 4 of 7

File: USPT

Apr 24, 2001

DOCUMENT-IDENTIFIER: US 6221603 B1

TITLE: Rolling circle amplification assay for nucleic acid analysis

Brief Summary Text (6):

Presently there are a number of assays for detection of nucleic acid sequences. These assays are sensitive and can produce detectable results with 100 target molecules or fewer. These assays are also specific, allowing accurate detection of specific sequences. The polymerase chain reaction (PCR) is one such method for amplification and detection of a specific sequence. This method consists of repeated cycles of denaturing a template strand of DNA, annealing matched primer pairs to the DNA, and extending the DNA from the primer using a DNA polymerase. A matched set of primers is used to amplify the sequence between the locations where the primers anneal. After each cycle, the resulting copy may act as a template for additional copying, allowing exponential amplification. Following the amplification of a DNA sequence, the sequence can be analyzed by sequencing or by restriction fragment analysis.

Brief Summary Text (24):

The above objects are achieved through methods and reagents for the high throughput analysis of genetic loci using padlock probes. In this assay, sets containing a plurality of probes are used to assay target nucleic acid sequences, such as genomic DNA, plasmids, viral genomic DNA, viral genomic RNA, cDNA or mRNA. Through the use of these sets of probes, a set of detection fragments are produced. The detection fragments are distinguishable by size and/or detectable label. Each detection fragment is produced if a target nucleic acid targeted by a corresponding probe is present. Multiplex assay by detection of size and detectable label allows detection of numerous fragments in a single reaction and analytical separation.

Brief Summary Text (28):

The plurality of padlock probes would hybridize to a plurality of loci on the target nucleic acid sequence. Under the ligation conditions, if the target nucleic acid sequence has the genotypic variant of interest, the probe will be ligated into an amplification target circle. The amplification target circles that are generated act as templates for the generation of tandem-sequence DNA. All of the probes that have been ligated to form amplification target circles may then be amplified in a single reaction by adding a primer and a DNA polymerase to the mixture. The DNA polymerase will attach at the primer sequence and will produce a strand of tandem-sequence DNA from the amplification target circle template. Each padlock probe that was ligated to form an amplification target circle will produce a unique tandem-sequence DNA strand. The tandem-sequence DNA is then digested to form non-tandem fragments. The plurality of padlock probes may be designed such that one enzyme, such as a restriction enzyme, may be used to digest all of the tandem-sequence DNA. Each padlock probe generates unique non-tandem fragments and each probe is designed such that the non-tandem fragments produced differ in length from the non-tandem fragments produced by any other padlock probe. In one embodiment, the padlock probes are designed to produce non-tandem fragments of 30-100 bp in length with each fragment differing in length from any other fragment by two base pairs.

Detailed Description Text (2):

The present invention enables the rolling circle amplification reaction to be used for the high throughput analysis of nucleic acid sequences. In this method a number of genetic variants or expressed genes may be assayed in a single reaction. The assay should prove especially valuable in assay of single nucleotide polymorphism alleles.

Detailed Description Text (10):

Several levels of multiplexing are possible using this system. First, each set of probes produces corresponding detection fragments which vary by size. Second,

additional sets of probes may be used in a single reaction container if each set of probes produces detection fragments which use a different detectable label. For example, two fragments of the same length may be distinguished by an optical detector if each fragment is associated with a separate optical label. Multiple sets of probes may be used simultaneously in a single reaction container. The reagents used with each probe could be the same except for the labeling reagent. Third, further multiplexing could be achieved by pooling target nucleic acid. Fourth, the detection fragments are sufficiently small to allow for multiple groups of fragments to be loaded onto a separation system such as a capillary in an electrophoresis system and continuously separated and detected. These four levels of multiplexing, alone or in combination, greatly increase throughput in analyzing target nucleic acid fragments.

Detailed Description Text (11):

Using this method of detection, a large number of loci or variants may be assayed at one time. For example, a set of probes may be designed to assay for 30 separate loci. This assay may be effected in a single reaction container and analyzed on a single system. These 30 loci could be generated in a small reaction container such as a microplate well, and would use the same reagents for ligation, amplification and restriction into non-tandem fragments. In addition, the amount of target nucleic acid in each reaction container is used to simultaneously assay numerous loci. Each reaction requires about 50 ng of target nucleic acid. The ability to simultaneously assay multiple loci in a single reaction container greatly reduces the cost of each locus assay. The resulting fragments may be analyzed in a single separation length (e.g. single capillary in a capillary electrophoresis array) in which the fragments are separated by length.

Detailed Description Text (39):

Within the constant region 25 of every stuffer section are sequences which are common to every padlock probe in a set of padlock probes. These include restriction enzyme site complementary regions 21, 23, a primer complementary region 27 and a detection probe complementary region 31. These identical elements allow the steps of amplification, restriction and labeling to occur under isothermal conditions using a single set of reagents with all steps occurring in a single reaction container. The variable region 29 has a length which is unique for each padlock probe in a set of padlock probes.

Detailed Description Text (46):

The method of the present invention allows the high throughput analysis of a large number of nucleic acid variants in a single reaction. Method can be automated to produce even higher throughput. The detailed steps of the method are as follows.

Detailed Description Text (91):

In a second example, throughput is further increased by the use of different labels to detect the presence of multiple fragments of the same length. In this method, three sets of padlock probes are provided. Each set contains 30 probes. Each individual probe in each set is designed to assay a variant at a nucleic acid locus. If the variant of interest is present, each probe in a set will, under ligation conditions, ligate to form an amplification target circle. Tandem-sequence DNA may be generated from the amplification target circle. The tandem-sequence DNA generated is then cut at a restriction enzyme site. The resulting detection fragments produced from each probe in the set of probes differ in length by two bases. If the length of the detection fragments varies from 40 to 100 bases long, 30 variants may be assayed with each set of probes. The probes in all three sets of probes have common restriction site complementary sites and primer complementary sites. The ligation, amplification and restriction steps may be performed in a single reaction container, such as a microplate well. For each set of probes, a maximum of 30 sets of detection fragments would be generated. Each set of padlock probes would have a detection probe sequence that is the same for each probe in the set but different from the detection probe sequence of each of the other two sets of padlock probes. Thus three detection probes would be needed to detect the detection fragments. Each of the three detection probes would have a unique optically detectable label. Analysis of the detection fragments on an analytical system which is able to discriminate four colors would allow detection of three fragments of the same size at the same time, with each fragment identified by color. The fourth color detectable by the analytical system would be used in a standardized size DNA ladder to aid in discrimination of variants. This gives the

analytical system a standardized reference point for simplified detection. In this manner, the three sets of probes could produce detection fragments of the same sizes which would be distinguishable. In a capillary array electrophoresis system, the three sets of probes could be analyzed in a single capillary in a capillary array electrophoresis system. This would allow higher throughput.

Detailed Description Text (92):

The multiplexing methods described allow much greater throughput for each assay. For example, in one method each set of padlock probes contains 30 probes which assay 30 variants and may produce 30 DNA fragments, each differing in length by 2 nucleotides. By labeling the fragments with different detectable labels, fragments of the same size may be differentiated by the detector. Thus three sets of padlock probes may be used in the reaction with a four-color detector while reserving one color for a standard DNA-sizing ladder. Thus, in a single reaction volume, 90 separate variants may be analyzed using many of the same reagents. For these 90 variants, the padlock probes will be designed such that a single primer may be used for the amplification of all of the probes.

CLAIMS:

13. The method of claim 12, wherein steps b, c, d, e and f all are carried out in a single reaction container.

☐ Generate Collection

L2: Entry 1 of 6

File: USPT

Oct 2, 2001

DOCUMENT-IDENTIFIER: US 6297010 B1

TITLE: Method for detecting and identifying mutations

Brief Summary Text (2):

This invention is in the field of molecular biology and medicine. More specifically, it relates to methods of detecting and identifying mutations in nucleic acid sequences.

Brief Summary Text (5):

Assays which detect the existence of nucleic acid mutations have been developed using various molecular biological techniques. One of the earliest methods involved the detection of restriction fragment length polymorphisms (RFLPs) using the Southern blotting technique. (Southern, E. M., J. Mol. Biol. 98:503-517 (1975)). RFLPs determine genetic variations in certain DNA fragments by cleaving the fragments with a type II restriction endonuclease. The differences in DNA length are due to the presence or absence of a specific endonuclease recognition site(s) and are detected using DNA hybridization with DNA probes after separation by gel electrophoresis.

Brief Summary Text (6):

Methods of detecting mutations which make use of polymerase chain reaction (PCR) have also been developed. In instances where the particular mutation has been identified, labeled primers can be used to determine whether a sample contains the known mutations. PCT/US93/04160 describes a method which allows perfectly matched DNA molecules to be separated from imperfectly matched molecules. The molecules can also be labeled to provide probes for identifying regions of heterozygosity in the genome.

Brief Summary Text (7):

In U.S. Pat. No. 5,217,863, Cotton et al. claims a method of detecting point mutations in sample DNA by hybridizing it to known DNA (without mutations) and subjecting the heteroduplex to hydroxylamine or osmium tetroxide and piperidine treatment. Hydroxylamine reacts with mismatched C and osmium tetroxide reacts with mismatched T (and to a lesser extent mismatched C), resulting in cleavage at the point of mismatch on addition of piperidine. The resulting material is then separated, for instance, by electrophoresis. If cleavage has occurred at one or more sites this will be apparent from the result of separation treatment, the number of fragments indicating the number of cleavages and hence the number of mutations of the type under consideration. However, the identity of the sequence(s) cannot be determined.

Brief Summary Text (8):

More recently, mutation-detecting assays have been developed that utilize proteins that recognize and bind to mismatched DNA heteroduplexes. (See, e.g., Modrich, Science 266:1959-1960 (1994) and U.S. Pat. No. 5,459,039). These proteins have been found in a variety of organisms in addition to E. coli. They act in concert to recognize and repair mismatches. In the simplest embodiment, heteroduplexes formed between reference and test DNAs are contacted with a mismatch recognition protein, such as MutS. The mixture is then passed over a nitrocellulose filter which binds the protein and any protein:DNA complexes. The presence of a mismatch in the contacted DNA is indicated by retention of the DNA:protein complex on nitrocellulose. However, this method indicates only the presence or absence of a mismatch, and does not directly allow for identification of the specific mutation(s).

Brief Summary Text (9):

Similarly, WO 95/12689, assigned to GeneCheck, Inc., describes contacting labeled heteroduplexed DNA with a labeled immobilized mismatch binding protein ("MBP") such as MutS. Binding, detected by direct or indirect methods, is indicative of a mismatch. Similarly, this method indicates only the presence or absence of a mismatch, and does

not directly allow for identification of the specific mutation(s). Along the same vein, WO 93/02216, assigned to Upstate Biotechnology, Inc. describes how mutations can be detected using a labeled antibodies specific for MBPs to determine if a mismatch is present. Again, the identity of the mismatch is not determined.

Brief Summary Text (10):

Methods have also been described which determine the general location of a mismatch using mismatch binding proteins. (See, WO 95/29258) Here, a test strand of nucleic acid potentially containing a mutation is hybridized to a reference strand known not to have a mutation. The duplex is contacted with a MBP and the complex is then treated with an exonuclease. The digestion of the nucleic acid terminates at the position of any bound MBP. The relative sizes of the resulting degradation products are analyzed, for example by electrophoresis, to determine the presence and approximate location of the mismatch.

Brief Summary Text (11):

U.S. Pat. No. 5,459,039 to Modrich et al. describes a method for detecting base sequence differences between homologous regions of two DNA molecules. In this method, the two strands are annealed and a protein which recognizes mismatches is added to form a DNA:protein complex. Modrich describes several labor-intensive methods of "localizing" the mismatch. For example, single-stranded gaps near the mismatch can be generated by contacting the DNA:protein complex with a defined mismatch correction system. The DNA is then cleaved with a single-stranded specific endonuclease and at least one restriction enzyme. The electrophoretic mobilities of the fragments are then compared. Alternatively, heteroduplexed DNA containing at least one GATC sequence may be contacted with a mixture of mutS, mutL, and mutH. Cleavage of the DNA indicates presence of a mismatch. However, the position of the mismatch is not determined.

Brief Summary Text (12):

Alternatively, the location of the mismatch can be identified by chemically modifying at least one strand of the DNA duplex in the vicinity of the bound mismatch recognition protein. Modrich et al. describes how chemical modification, such as hydroxyl radical cleavage, can be accomplished by modifying the MutS protein to create a binding site for a metal ion which can catalyze formation of hydroxyl radicals which in turn will attack and cleave at least one strand of bound DNA in the vicinity of the mismatch.

Brief Summary Text (14):

However, none of these methods directly identify the precise sequence of a mutation. Moreover, none of these methods provides for a high-throughput system for identifying unknown mutations. Currently, PCR amplification may be utilized to amplify region(s) of DNA, followed by sequencing of the PCR product(s). However, genes which are the loci of known disease-causing mutations may cover many kilobases of DNA. The cost and labor required to sequence every patient DNA sample over these important regions would make the detection of pathogenic mutations extremely slow and prohibitively expensive. Thus, one or more "mutation scanning" methodologies, such as those described above, is typically applied to detect the presence of mutations and limit the regions to be sequenced to those containing the potential alterations. This process is still time-consuming and laborious, since the scanning process does not aid in the subsequent process of sequence determination, which itself may pose separate and unique difficulties associated with template quality and quantity, as well as the inherent limitation of current methods to provide sequence in excess of a certain number of nucleotides from a primer (typically 600). Thus, a need exists which both indicates the presence of unknown mutations and which directly provides the sequence of the alteration(s). This invention satisfies these needs and provides related advantages as well.

Brief Summary Text (16):

This invention provides a method for identifying one or more genetic alterations in a sample polynucleotide strand by contacting the sample polynucleotide strand with a reference polynucleotide strand substantially homologous to the sample strand under conditions suitable to form a duplex of the sample and reference strands. The sequence may be in whole or in part, unknown. The duplexes are then contacted with an agent which recognizes and protects base pair mismatches under conditions which allow the agent to bind to the duplex at the mismatch to form a duplex:protein complex.

Preferably, the agent is an MBP, a functional fragment, analog or variant, thereof. The complex is then contacted with an agent that removes unprotected base pairs such as a 3'.fwdarw.5' exonuclease to form a single-stranded region terminating at the position of the agent. To provide a unique position from which to sequence, the 3' terminus is then extended ("backfilled") to terminate at a position penultimate to the occurrence of a chosen nucleotide(s). This is performed using a DNA polymerase and a mixture of 2 or 3 different deoxynucleoside triphosphates. As will be apparent by the following discussion, this backfilling reaction is not required for identifying the presence of mutations. A partially-degenerate "adapter" oligonucleotide of predetermined sequence having the chosen nucleotide (as described above) at its 5' terminus is then ligated onto the sample strand. A primer complementary to a portion of the partially-degenerate oligonucleotide and a second primer complementary to a nucleotide sequence 5' to the region examined are then used to amplify the sample strand. Optionally, the sample polynucleotides can be separated from the reference polynucleotide prior to amplification to eliminate sequence information from the reference strand and to reduce assay "noise". Presence of a mutation is indicated by the production of an amplified product. The mutation is then identified by sequencing the product using standardized sequencing methods well known in the art.

Brief Summary Text (19):

This invention also provides a method for identification of one or more mutation(s) in sample polynucleotides by immobilizing a plurality of sample polynucleotides or reference polynucleotides on a single solid support. The sample polynucleotides may have identical or non-identical sequence. The sequence may be in whole or in part, unknown. Reference polynucleotides or sample polynucleotides (as appropriate) are then contacted with the immobilized polynucleotides to form reference:sample duplexes. As noted above, the sample polynucleotides may have identical or non-identical sequence. These duplexes are contacted by an agent which recognizes base pair mismatches under conditions which allow the agent to bind to the duplex at the mismatch to form a duplex:agent complex. Preferably, the agent is an MBP, a functional fragment, analog or variant, thereof. The complex is digested with a 3'-5' exonuclease, and backfilled as described above. A single-stranded adapter oligonucleotide is then ligated to the duplex termini. The sample polynucleotides are amplified using primers complementary to the adapter oligonucleotide and a sequence 5' to the examined region on the sample strand and sequenced to identify the mutation. Optionally, the sample polynucleotide can be separated from the reference polynucleotide prior to amplification to eliminate amplification of the reference strand DNA and reduce "noise."

Brief Summary Text (20):

In an alternative embodiment, the sequences of the polynucleotides may be in whole or in part, unknown. They may be comprised of PCR or multiplex (i.e., a plurality) of PCR products, restriction fragments, cDNA or other DNAs which are substantially double-stranded. The sample polynucleotides may have identical or non-identical sequence. A (set of) reference:sample duplex(es) is formed by contacting the sample polynucleotide strand with a reference polynucleotide strand substantially homologous to the sample strand under conditions suitable to form a duplex. If the polynucleotides are in excess of 1 kbp in size, the product duplex may be degraded by a double-strand cleaving activity to reduce the average size of the fragments. The duplexes are then contacted with an agent which recognizes and protects base pair mismatches under conditions which allow the agent to bind to the duplex at mismatches to form duplex:protein complex(es). Preferably, the agent is an MBP, a functional fragment, analog or variant, thereof. The complex is then contacted with an agent that removes unprotected base pairs such as a 5'.fwdarw.3' exonuclease to form a single-stranded region terminating at the position of the agent. The exonuclease is then removed or inactivated. A pair of "adapter" oligonucleotides of predetermined sequence, both having a short tract of degenerate sequence at their 3' ends are then ligated onto the digested sample strand 5' termini. The undigested single-stranded 3' overhangs left by the exonuclease (and the unligated adapters) are then degraded using a single-strand specific 3'.fwdarw.5' exonuclease. The "trimmed" 3' termini are then extended on the ligated adapter sequence template to produce a double-stranded product. A pair of primers complementary to portions of the fixed sequence element of each of the partially-degenerate adapters are then used to amplify both strands. Presence of a mutation is indicated by the production of an amplified product. The products are then cloned. The mutation(s) is then identified by sequencing the cloned product(s) using sequencing methods well known in the art.

Drawing Description Text (2):

FIG. 1A is a schematic depicting the first steps of one embodiment of the present invention. A biotinylated reference DNA strand is annealed to sample DNA and the duplex contacted with a protein which recognizes mismatches, such as MutS. A 3'.fwdarw.5' exonuclease removes the nucleotides unprotected by the protein.

Drawing Description Text (3):

FIG. 1B is a schematic continuing from FIG. 1A. The exonuclease-generated 3' termini are extended by a DNA polymerase with a mixture of two or three deoxynucleoside triphosphates. The exonuclease-treated, polymerase filled DNA is captured on a solid support via biotin-avidin interactions. A partially degenerate adapter-primer is ligated to the 3' ends of the strands. The sample strand is dissociated from the reference strand. The sample strand is then amplified prior to sequencing using the adapter-complementary primer and the primer corresponding to the 5' end of the sample strand.

Drawing Description Text (4):

FIG. 2 is a photograph of an ethidium bromide stained agarose gel showing amplified protected fragments from a typical assay. A set of site-directed mutants in a 260 b.p. amplicon containing a portion of the cystic fibrosis transmembrane regulator exon 7 were assayed using mutS. "Reference Strand" indicates the nucleotide at position 154 of the amplicon which was present in the sense strand of the reference DNA. "Basepair" indicates the basepair formed at the same position with each of four non-biotinylated sample DNAs, each varying in the identity of the nucleotide at position 154.

Drawing Description Text (6):

FIG. 4A is a schematic depicting the first steps of another embodiment of this invention. Two nucleic acid samples differing in sequence at one or more sites are heated and annealed to generate a heteroduplex DNA(s) containing mismatched nucleotides at the difference loci. The heteroduplex is contacted with MutS or other mismatch-binding protein. The complex is then contacted with a 5'.fwdarw.3' exonuclease such as T7 gene 6 exonuclease. The exonuclease is removed.

Drawing Description Text (7):

FIG. 4B is a schematic continuing from FIG. 4A. A 3'-partially-degenerate adapter oligonucleotide is ligated to the 5' ends of the strands. The product(s) are contacted with a single-strand-specific 3'.fwdarw.5' exonuclease such as exonuclease I. The newly-generated 3' termini are extended with a DNA polymerase to generate a full-duplex adapter sequence at each end. The product(s) is then amplified by PCR.

Detailed Description Text (6):

The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes single-, double-stranded and triple helical molecules. "Oligonucleotide" refers to polynucleotides of between about 6 and about 100 nucleotides of single- or double-stranded DNA or RNA. Oligonucleotides are also known as oligomers and may be isolated from genes, or chemically synthesized by methods known in the art. A "primer" refers to an oligonucleotide, usually single-stranded, that provides a 3'-hydroxyl end for the initiation of nucleic acid synthesis.

Detailed Description Text (7):

The following are non-limiting embodiments of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A nucleic acid molecule may also comprise modified nucleic acid molecules, such as methylated nucleic acid molecules and nucleic acid molecule analogs. Analogs of purines and pyrimidines are known in the art, and include, but are not limited to, aziridinycytosine, 4-acetylcytosine, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethyl-aminomethyluracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine,

3-methylcytosine, 5-methylcytosine, pseudouracil, 5-pentyluracil and 2,6-diaminopurine. The use of uracil as a substitute for thymine in a deoxyribonucleic acid is also considered an analogous form of pyrimidine. These polynucleotides are intended to at least refer to the sample strand and the reference strand.

Detailed Description Text (8):

As used herein, "base pair," also designated "bp," refers to the complementary nucleic acid molecules; in DNA the purine adenine (A) is hydrogen bonded with the pyrimidine base thymine (T), and the purine guanine (G) with pyrimidine cytosine (C), also known as Watson-Crick base-pairing. A thousand base pairs is often called a kilobase, or kb. A "base pair mismatch" refers to a location in a nucleic acid molecule in which the bases are not complementary Watson-Cricks pairs.

Detailed Description Text (9):

The term "duplex" refers to the complex formed between two strands of hydrogen-bonded, complementary nucleic acid molecules. A duplex need not be entirely complementary, but can contain one or more mismatches or one or more deletions or additions. A duplex is sufficiently long-lasting to persist between formation of the duplex or complex and subsequent manipulations, including, for example, any optional washing steps.

Detailed Description Text (10):

As used herein, the term "reference strand" or "wild-type strand" refers to the nucleic acid molecule or polynucleotide having a sequence prevalent in the general population that is not associated with any disease or discernible phenotype. It is noted that in the general population, wild-type genes may include multiple prevalent versions that contain alterations in sequence relative to each other and yet do not cause a discernible pathological effect. These variations are designated "polymorphisms" or "allelic variations." It is therefore possible to prepare multiple reference strands, thereby providing a mixture of the most common polymorphisms. Alternatively, one reference strand may be used that has been selected for its particular sequence. The reference strand can also be chemically or enzymatically modified, for example to remove or add methyl groups. In one or more embodiments, the reference strand is comprised of a PCR product identical at least in part to the sequence prevalent in the general population. It is intended to include, but not be limited to polynucleotides as defined above, i.e., a gene or gene fragment, restriction fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.

Detailed Description Text (11):

In a preferred embodiment, the reference strand or wild-type strand comprises a portion of a particular gene or genetic locus in the patient's genomic DNA known to be involved in a pathological condition or syndrome. Non-limiting examples of genetic syndromes include cystic fibrosis, sickle-cell anemia, thalassemias, Gaucher's disease, adenosine deaminase deficiency, alpha-1-antitrypsin deficiency, Duchenne muscular dystrophy, familial hypercholesterolemia, fragile X syndrome, glucose-6-phosphate dehydrogenase deficiency, hemophilia A, Huntington disease, myotonic dystrophy, neurofibromatosis type 1, osteogenesis imperfecta, phenylketonuria, retinoblastoma, Tay-Sachs disease, and Wilms tumor (Thompson and Thompson, Genetics in Medicine, 5th Ed.). It is intended to include, but not be limited to polynucleotides as defined above, i.e., a PCR product, a gene, a gene fragment, a restriction fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.

Detailed Description Text (12):

In another embodiment, the reference strand comprises part of a particular gene or genetic locus that may not be known to be linked to a particular disease, but in which polymorphism is known or suspected. For example, obesity may be linked with variations in the apolipoprotein B gene, hypertension may be due to genetic variations in sodium or other transport systems, aortic aneurysms may be linked to variations in .alpha.-haptoglobin and cholesterol ester transfer protein, and alcoholism may be related to variant forms of alcohol dehydrogenase and mitochondrial aldehyde dehydrogenase. Furthermore, an individual's response to medicaments may be affected by variations in drug modification systems such as cytochrome P450s, and susceptibility

to particular infectious diseases may also be influenced by genetic status. Finally, the methods of the present invention can be applied to HLA analysis for identity testing. It is intended to include, but not be limited to polynucleotides as defined above, i.e., a gene, a gene fragment, a restriction fragment, a PCR product, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.

Detailed Description Text (13):

The term "sample strand" or "patient strand" refers to the polynucleotide having unknown sequence and potentially containing one or more mutations or mismatches as compared to the reference strand. This may be a PCR product amplified from patient DNA or other sample(s). It also is intended to include, but not be limited to polynucleotides as defined above, i.e., a gene, a gene fragment, a restriction fragment, a PCR product, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.

Detailed Description Text (15):

The term "genetic alterations" or "mutations" is used to refer to a change from the wild-type or reference sequence of one or more nucleic acid molecules. It refers to base pair substitutions, additions and deletions of a sample strand when compared to a reference strand.

Detailed Description Text (17):

As used herein, the term "agent which recognizes and protects or masks the polynucleotide" from chemical or enzymatic degradation is any agent, proteinaceous or otherwise, which provides this functional activity when used in the method of this invention. In one embodiment, this agent is a mismatch binding protein or "MBP". MBP refers to the group of proteins which recognize and bind to nucleotide mismatches in polynucleotide duplexes. By recognizing and binding to improperly paired nucleotide strands, these proteins are involved in the complex pathway of genetic repair. Repair is generally initiated by the binding of the protein MutS to the mismatch. (See, Modrich (1994), supra). MutL then complexes with the MutS bound to the mismatch, which in turn complexes with MutH and leads to the activation of a GATC endonuclease associated with MutH. Cooperative action of MutS, MutL and DNA helicase (MutU) is required to remove the mismatch region, which is then repaired using polymerases and other enzymes.

Detailed Description Text (19):

Mismatch repair proteins for use in the present invention may be derived from E. coli (as described above) or from any organism containing mismatch repair proteins with appropriate functional properties. Non-limiting examples of useful proteins include those derived from Salmonella typhimurium (MutS, see, Su, S. S. and Modrich, P., Proc. Natl. Acad. Sci. 84:5057-5061 (1986); MutL); Streptococcus pneumoniae (HexA, HexB); Saccharomyces cerevisiae ("all-type," MSH2, MLH1, MSH3); Schizosaccharomyces pombe (SWI4); mouse (rep 1, rep3); and human ("all-type," hMSH2, hMLH1, hPMS1, hPMS2, duc1). Preferably, the "all-type" mismatch repair system from human or yeast cells is used (Chang et al., Nuc. Acids Res. 19:4761 (1991); Yang et al., J. Biol. Chem. 266:6480 (1991)). In another embodiment, heteroduplexes formed between patients' DNA and wild-type DNA as described above are incubated with human "all-type" mismatch repair activity that is purified essentially as described in International Patent Application WO/93/20233. In another embodiment, heteroduplexes formed between patients' DNA and wild-type DNA as described above are incubated with p53 or its C-terminal domain (Lee, et al., Cell 81:1013-1020 (1995)).

Detailed Description Text (22):

The term "exonuclease" refers to an enzyme that cleaves nucleotides sequentially from the free ends of a linear nucleic acid substrate. Exonucleases can be specific for double or single stranded nucleotides and/or directionally specific, for instance, 3'.fwdarw.5' and/or 5'.fwdarw.3'. Some exonucleases exhibit other enzymatic activities, for example, native T7 DNA polymerase is both a polymerase and, in the absence of deoxynucleoside triphosphate, an active 3'.fwdarw.5' exonuclease. Exonuclease III removes nucleotides one at a time from the 3'-end of duplex DNA, exonuclease VII removes several nucleotides at a time from both ends of

single-stranded DNA and lambda exonuclease removes nucleotides having attached 5' phosphate groups from the 5' end of duplex DNA.

Detailed Description Text (23):

The term "polymerase chain reaction" or "PCR" refers to a method for amplifying a DNA base sequence using a heat-stable polymerase such as Taq polymerase, and two oligonucleotide primers, one complementary to the (+)-strand at one end of the sequence to be amplified and the other complementary to the (-)-strand at the other end. Because the newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, successive rounds of primer annealing, strand elongation, and dissociation can produce rapid and highly specific exponential amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.

Detailed Description Text (27):

Reference DNA can be synthesized by chemical means or, preferably, isolated from any organism by any method known in the art. The organism will have no discernible disease or phenotypic effects. This DNA may be obtained from any cell source, tissue source or body fluid. Non-limiting examples of cells sources available in clinical practice include blood cells, buccal cells, cerviovaginal cells, epithelial cells from urine, fetal cells, or any cells present in tissue obtained by biopsy. Body fluids include urine, blood, cerebrospinal fluid (CSF), and tissue exudates at the site of infection or inflammation. DNA is extracted from the cells or body fluid using any method known in the art. Preferably, at least 5 pg of DNA is extracted. The extracted DNA can be used without further modification or stored for future use.

Detailed Description Text (28):

Preferably, one or more specific regions in the extracted reference polynucleotide are amplified by PCR using a set of PCR primers complementary to genomic DNA separated by up to about 500 base pairs. PCR conditions found to be suitable are described below in the Examples. It will be understood that optimal PCR conditions can be readily determined by those skilled in the art. (See, e.g., PCR 2: A PRACTICAL APPROACH (1995) eds. M. J. McPherson, B. D. Hames and G. R. Taylor, IRL Press, Oxford).

Detailed Description Text (29):

PCR products can be purified by a variety of methods, including but not limited to, microfiltration, dialysis, gel electrophoresis and the like. It is desirable to remove the polymerase used in PCR so that no new DNA synthesis can occur.

Detailed Description Text (37):

Suitable supports include, but are not limited to, beads or microtiter plates that are coated with a molecule capable of binding a polynucleotide to the solid support and which is compatible with this assay. Avidin can be used to bind a strand that has had biotin attached, for example by using biotin-conjugated PCR primers. In addition, antibodies can be used to attach the reference strand to any of the above mentioned solid supports by coating the surfaces with the antibodies and incorporating an antibody-specific hapten into the target DNA, e.g., digoxigenin, fluorescent dyes, eosin, DNP and the like. In a preferred embodiment, the reference or patient strand that has been amplified using biotinylated primers is bound to streptavidin-coated beads (CPG, Inc., Lincoln Park, N.J.). In one embodiment, the reference duplex is biotinylated at both 5' termini. This significantly reduces noise, and allows detection of weak mismatches (i.e., C:C).

Detailed Description Text (41):

When an agent such as a MBP binds to a mutation in a heteroduplex, it protects that portion of the DNA from chemical or enzymatic degradation. Similarly, the ends bound to a solid support, for instance by conjugation to a hapten, or otherwise protected will not be subject to degradation. Accordingly, in a preferred embodiment, after adding the MBP, an enzyme having exonuclease activity is added under conditions sufficient to remove nucleotides which are not bound by the MBP or coupled to a solid support. Preferably, a unidirectional exonuclease with high activity is used. In a preferred embodiment, the exonuclease is the 3'.fwdarw.5' exonuclease of T7 DNA polymerase and the DNA is digested for 3-5 minutes at 37.degree. C. as shown in the bottom panel of the schematic of FIG. 1. The portion of the duplex bound by the MBP will be protected from exonuclease activity, thus the region of mismatch will remain

double-stranded.

Detailed Description Text (42):

The top panel of FIG. 1B shows how oligonucleotides of predetermined sequence can be added onto each strand of duplex after exonuclease treatments. In one embodiment, the exonuclease is removed, then a mixture of three nucleoside triphosphates, preferably .alpha.-S-dGTP, .alpha.-S-dCTP, and .alpha.-S-TTP are added and the mixture incubated for about 5 minutes at 37.degree. C. with an agent having DNA polymerase activity. The reaction is quenched for example, by addition of a high-salt buffer. Advantageously, this may be accomplished by direct capture of the products upon a solid support and washing, if the products are not already bound to the solid support, although other means may be utilized, such as deproteinization and ethanol precipitation, for example. Where the hapten is biotin, a preferred solid support is streptavidin attached to magnetic particles. Binding can be obtained by incubating the solid support and haptenylated duplex for about 30 minutes at room temperature.

Detailed Description Text (45):

After removal of the MBP, the mutated sequence can be directly determined in a variety of ways. One embodiment is shown in FIGS. 1A and 1B. FIG. 1B shows how the washed, protein-free, backfilled, reference:sample duplex is contacted with a 5'-phosphorylated oligonucleotide (adapter) preferably having the sequence: 5'-pQZNNX, where N is an equimolar mixture of all four nucleotides, Q is any predetermined nucleotide, preferably A, and Z is any predetermined nucleotide or a mixture, preferably an equimolar mixture of all four nucleotides. X is sequence complementary to a primer having similar Tm as the primer(s) used to generate and analyze DNA, terminated with a blocking group such as a cordocypin (3' deoxyadenosine), phosphate, propyl group or the like. As shown in FIG. 1A, the sequence of the adapter is 5'-pANNXX.

Detailed Description Text (46):

Prior to ligation, the immobilized digested products can be incubated with single stranded DNAs or RNAs complementary to sequences within about 50 nucleotides 5' to the regions from which signals are undesirable. Due to inherent inaccuracies in chemical oligonucleotide synthesis and/or damage which is incurred during their synthesis, deprotection, or purification, significant nonspecific signal is generated from mismatches produced within the PCR primer sequences which can reduce assay sensitivity. These false signals may be advantageously blocked by incubation of the immobilized products with oligonucleotides complementary to the primer sequences prior to addition of the adapter and ligase.

Detailed Description Text (47):

At this point, FIG. 1B shows how the sample strand is separated from the reference strand for sequencing. Preferably, approximately 5 M betaine (N,N,N-trimethylglycine) is used for the elution of the sample strand ligation product. Betaine reduces background (noise) and minimizes the effect of that base composition surrounding the locus may have on the thermal stability of the duplex (see, for example, Rees, W. A., et al. Biochemistry (1993) 32:137-44) and thus on the ability to detect a sequence change. This compound also lowers the Tm of the polynucleotide duplexes (Rees, W. A., et al., supra.) enabling strand separation to be accomplished at room temperature. Other methods of releasing the sample strand can also be employed.

Detailed Description Text (48):

The released strand can then be directly amplified using a primer complementary to sequence X of the adapter and a second primer complementary to a sequence within the original DNA. The latter primer may be biotinylated to aid in the subsequent purification and sequencing of the product DNA. The amplified protected fragments can be resolved by electrophoresis in agarose or acrylamide gels or by other means such as HPLC, thin layer chromatography, size exclusion chromatography or capillary gel electrophoresis. The presence of amplified products of specific sizes by this analysis identifies samples which contain mutations or polymorphisms in the DNA. Each sequence alteration will produce a double-stranded DNA of unique size, thus allowing for the detection of more than one change in the sequence.

Detailed Description Text (49):

The amplified products, if present, may also be isolated and directly sequenced using

a primer complementary to the adapter. Since each of the product DNAs are derived from patient DNA strand, only the mutant sequence is present. The expectation of only one sequence (as opposed to a mixture of mutant and normal sequence in the case of heterozygotes) also clearly distinguishes sequence alterations from sequencing ambiguities. Sequencing by extension of the primer complementary to the adapter usually places the mutation within 50 nucleotides. As will be recognized by those skilled in the art, sequencing close to the primer substantially improves the reliability of the sequence obtained. In addition, this approach also eliminates the need to separate (by cloning for example) mutant DNAs containing small deletions or insertions, which otherwise would generate nested sequences which pose difficulties in interpretation by direct sequence analysis.

Detailed Description Text (51):

The present invention offers an alternative, cost-effective method for localizing a disease-causing gene. Briefly, a polynucleotide from affected individuals is hybridized with a normal or wild-type polynucleotide as described above to form mismatch regions at the site of the mutation. Preferably, genomic DNA is digested with a restriction endonuclease which produces fragments on average several hundred nucleotides in size, although similar sized fragments of DNA corresponding to the chromosomal location may also be amplified from the patient's genomic DNA prior to inclusion in the hybridization reaction. Alternatively, larger genomic fragments may be utilized if the hybridization reaction is followed by treatment with an activity which cleaves both strands of the polynucleotide at opposing or nearly opposing positions. Such agents include restriction endonucleases, micrococcal nuclease, or DNase I in the presence of manganese ions. The hybrids are then treated in a protection experiment such as described above so that mismatch regions are recognized, bound and protected from digestion. There is no need to perform a "backfill" reaction. Any 5'.fwdarw.3' exonuclease may be utilized which is blocked by the binding of the MBP to the mismatch, including T7 gene 6 exonuclease or lambda exonuclease. The preferred exonuclease is T7 gene 6 exonuclease. A mixture of two oligonucleotide adapters of predetermined sequence are then ligated to the termini resulting from digestion. Any overhanging ends not subject to degradation by the exonuclease are then "trimmed" by a second 3'.fwdarw.5' single-strand specific exonuclease. Non-limiting examples may be exonuclease I (3'.fwdarw.5'), exonuclease VII (5'.fwdarw.3' and 3'.fwdarw.5'), or a DNA polymerase having exonuclease activity such as T4 or T7 DNA polymerase in the presence of nucleoside triphosphates. The preferred enzyme is exonuclease I. The "trimmed" termini generated by the second exonuclease are then extended with a DNA polymerase upon the ligated adapter template strands to copy the sequence of the second adapter into the 3' end of the protected product. The region with added adapter sequences is then amplified by PCR or other means. The products are then cloned. Finally, the sequence of the cloned DNA, which comprises the protected region in the vicinity of the mismatch is determined by methods well understood in the art.

Detailed Description Text (52):

It will be immediately understood by practitioners of the art that this approach will generate a large population of products from naturally-occurring but otherwise innocent variations in DNA sequence, referred to as polymorphisms. Such sequence variations will generate mismatches that are indistinguishable from disease-causing mutations. To eliminate these variations from the population, a variation of the method of "subtractive hybridization" (U.S. Pat. Nos. 5,436,142 and 5,501,964) is performed. The mismatch binding-protection-amplification experiment is repeated with a pool of DNAs from unaffected individuals ("normal control" population) to generate a set of normal control probes. The primers to amplify this set are designed to not cross-hybridize with the primers used for amplification of the patient sample, and in addition contain one or more haptens, the preferred being biotin, which enable removal of the control probes and any sequences which can hybridize with them. The sample PCR products are mixed with an excess of normal control probe set, the mixture denatured by heating, reannealed, and those sequences hybridizing with the control probes removed by binding to a solid support bearing a hapten-binding moiety such as streptavidin. The unbound products are then reamplified utilizing the same set of primers used to amplify the patient sample. These products are then cloned and sequenced. It will be understood that the efficiency of hybridization and/or the abundance of naturally-occurring variants in the population may not be sufficiently high to remove all polymorphisms from the population of patient sample PCR products.

To overcome this difficulty, the process may be repeated as many times as is required to select against polymorphic sequences. The process may be followed by conducting the experiment on DNA from an individual with a known mutation and following the abundance of the sequence in the PCR population by hybridization. Finally, the products can also be cloned in tandem arrays by including restrictions sites in the adapters which permit end-to-end ligation of the amplified protected fragment inserts prior to cloning (see, for example, SAGE patent WO 97/10363).

Detailed Description Text (56):

As is known in the art, high density arrays of bound nucleotides can be produced for high-throughput screening. The methods of the present invention are particularly suitable for high-throughput analysis of DNA, i.e., the rapid and simultaneous processing of DNA samples derived from a large number of patients. Furthermore, in contrast to other methods for de novo mutation detection, the methods of the present invention are suitable for the simultaneous analysis of a large number of genetic loci in a single reaction; this is designated "multiplex" analysis. Therefore, for any one sample or for a multiplicity of samples, the present invention allows the analysis of both intragenic loci (several regions within a single gene) and internecine loci (several regions within different genes) in a single reaction mixture. The manipulations involved in practicing the methods of the present invention lend themselves to automation, e.g., using multiwell microtiter dishes as a solid support or as a receptacle for, e.g., beads; robotics to perform sequential incubations and washes; and, finally, automated sequencing using commercially available automated DNA sequencers. It is contemplated that, in a clinical context, 500 patient DNA samples can be analyzed within 1-2 days in a cost-effective manner (less than \$50.00/sample).

Detailed Description Text (60):

Preparation of Sample DNA

Detailed Description Text (61):

Whole blood samples collected in high glucose ACD Vacutainers.TM. (yellow top) were centrifuged and the buffy coat collected. The white cells were lysed with two washes of a 10:1 (v/v) mixture of 14mM NH₄Cl and 1 mM NaHCO₃, their nuclei were resuspended in nuclei-lysis buffer (10 mM Tris, pH 8.0, 0.4M NaCl, 2 mM EDTA, 0.5% SDS, 500 .mu.g/ml proteinase K) and incubated overnight at 37.degree. C. Samples were then extracted with a one-fourth volume of saturated NaCl and the DNA was precipitated in ethanol. The DNA was then washed with 70% ethanol, dried, and dissolved in TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA.)

Detailed Description Text (62):

Alternatively, Buccal cells were collected on a sterile cytology brush (Scientific Products) or female dacron swab (Medical Packaging Corp.) by twirling the brush or swab in the inner cheek for 30 seconds. DNA was prepared as follows, immediately or after storage at room temperature or at 4.degree. C. The brush or swab was immersed in 600 .mu.l of 50 mM NaOH contained in a polypropylene microcentrifuge tube and vortexed. The tube, still containing the brush or swab, was heated at 95.degree. C. for 5 min, after which the brush or swab was carefully removed. The solution containing DNA was then neutralized with 60 .mu.l of Tris, pH 8.0, and vortexed again (Mayall et al., J. Med. Genet. 27:658 (1990)). The DNA was stored at 4.degree. C.

Detailed Description Text (65):

The amplified sample DNA was separately heated and annealed in the presence of each biotinylated reference DNA. PCR products generated with Pfu DNA polymerase (Stratagene) were purified by deproteinization and sequential washing on a Centricon 100 filter (Amicon, Inc., Beverly Mass.). Five picomoles of each product DNA were mixed in 100 mM NaCl, 1 mM EDTA, 10 mM Tris.cndot.HCl pH7.5 and annealed by heating to 95.degree. C. for 5 min. followed by slow cooling to 50.degree. C. over a period of 90 min. (0.5.degree. C. min.sup.-1).

Detailed Description Text (68):

The annealed duplex (0.5 pmol total) was contacted with a mixture of 5 pmol of E. coli MutS protein (Amersham) and 5 pmol Taq MutS protein (Epicentre) on ice for 30 min. in 20 .mu.l 7 mM MgCl₂, 5 mM DTT, 40 mM HEPES pH6.5. Ten units of T7 DNA polymerase was added and the DNA digested for 4 minutes at 37.degree. C. A mixture of three nucleoside triphosphates, .alpha.-S-dGTP, .alpha.-S-dCTP and .alpha.-S-dTTP was added

and the reaction incubated for 5 minutes at 37.degree. C. High-salt buffer ("B&W": 1M NaCl, 10 mM Tris pH7.5, 1 mM EDTA, 0.1% Tween 80) was added to quench the reaction. The digested products were then captured by addition of 10 .mu.l (100 .mu.g) MPG streptavidin magnetic particles (CPG, Inc.) and incubation for 30 min. at room temperature. The particles were washed once with B&W buffer and once with ligation buffer (50 mM Tris pH7.5, 5 mM MgCl.sub.2, 1 mM DTT, 100 .mu.M ATP, and 100 .mu.g/ml acetylated BSA).

Detailed Description Text (74):

Following blocking, the products were contacted with a 5'-phosphorylated adapter having the sequence 5'-pANNNX, where N was an equimolar mixture of all four nucleotides and X was a sequence complementary to a primer having a similar Tm as the primer used to generate the sample strand. Ten (10) .mu.l of ligation buffer containing 50 pmol of the oligonucleotide 5'-ANNNTGAGGCTGCGGACCGTGGGCCCK (SEQ ID NO: 1), where K was a cordecypin (3' deoxyadenosine) residue and 5 Weiss units T4 DNA ligase was added and the mixture incubated for 30 min. at room temperature.

Detailed Description Text (76):

The amplified products were resolved by agarose or acrylamide gels, or in some instances by HPLC or capillary gel electrophoresis. In the example shown, a 3% MetaPhor agarose gel was utilized. Because each genetic alteration produced a double-stranded DNA of a unique size, more than one change in the sequences could be detected.

Detailed Description Text (80):

A clone of the Sau3A fragment encompassing exon 7 of the CFTR gene incorporated in to the PCR product insertion site in pAT2.1 (InVitroGen) is cleaved with EcoRI to release the cloned insert, which is purified free of vector DNA by electrophoresis. One .mu.g of the insert DNA is dephosphorylated for 60' with 0.1U calf intestinal phosphatase and deproteinized. Thiophosphates are introduced into the 5' termini by incubation for 30 min. with 5U T4 polynucleotide kinase and 1 mM ATP.gamma.S in 50 mM Tris.HCl pH7.5, 10 mM MgCl.sub.2, 1 mM DTT, and the unincorporated ATP.gamma.S removed by chromatography over a spin column of Sephadex G50 equilibrated with 50 mM HEPES pH7.5 1 mM EDTA. Biotins are added to the termini by addition of 1 mM 1-biotinamido-4-[4'-(maleimidomethyl)-cyclohexane-carboxamido]butane. ("Biotin-BMCC", Pierce) and incubation for 2 hours at room temperature. Unreacted reagent is removed by spin column chromatography, and the DNA quantitated by absorbance.

Detailed Description Text (81):

Patient DNA (10 .mu.g) is digested to completion with Sau3A, and mixed with 0.5 picograms of biotinylated reference DNA in 1.5M sodium thiocyanate, 120 mM sodium phosphate pH6.8, 10 mM EDTA with 8% (v/v) freshly distilled phenol. The mixture is heated to 100.degree. C. and chilled on ice. Heteroduplexes are formed by incubation in a thermal cycler at 37.degree. C., while heating intermittently (every 15 min.) to 65.degree. C. for two minutes for a total period of 24 h. The mixture is then extracted once with chloroform and chromatographed over a G50 Sephadex spin column to remove annealing buffer components.

Detailed Description Text (82):

One .mu.g of the above heteroduplex DNA preparation is used in the same manner as the amplicon DNA as described in examples 3 and 4, except that the betaine eluate is amplified with PCR using a set of primers, the first member which is complementary to the adapter sequence (sequence 1 below) and the other complementary to sequence in either the 5' or 3' regions outside the exon boundaries, but within the Sau3A fragment sequence (sequences 2 and 3 below). The products appearing as bands which are distinguishable from samples from normal (control) DNA are excised and sequenced using a primer of the same sequence as sequence 1 below.

Detailed Description Text (89):

In some cases, it is advantageous to suppress signals arising from the occurrence of common mutations and polymorphisms in same DNA(s). For example, a large fraction of patient samples suspected of containing mutant DNA sequences within the CFTR gene contain one .DELTA.F508 allele. About 70% of the total mutant alleles in the population consist of .DELTA.F508. Thus, when analyzing this gene, a signal corresponding to this mutation will frequently be found. Such signal(s) may in some

cases interfere with detection of other mismatches within the same regions which are more weakly recognized by MutS. However, these signals may be selectively suppressed inclusion of a peptide nucleic acid (PNA) complementary to the allele in the PCR reaction (Orum, et al., Nucl. Acids. Res. 21:5332-36 (1993)).

Detailed Description Text (92):

The experiments described below are performed to rapidly localize and sequence a genomic region corresponding to a disease-causing gene. A multiplex family in which a genetic disease is expressed is identified using standard clinical indicators. DNA samples are obtained from affected and unaffected individuals as described above; if by patterns of transmission the disease appears to be an autosomal recessive syndrome, DNA samples are obtained from those individuals presumptively heterozygous for the disease gene.

Detailed Description Text (93):

DNA from heterozygous individual(s) prepared as described in example 1 is digested with Alu I, heat denatured and self-annealed. Ten micrograms of Alu-digested genomic DNA is heated to 100.degree. C. for 10 min. in 50 .mu.l 1.5M sodium thiocyanate, 120 mM sodium phosphate pH6.8, 10 mM EDTA and 8% freshly-distilled phenol. The mixture is chilled on ice, and then placed in the thermal cycler and cycled for 2 min. at 65.degree. C. followed by 15 min. at 37.degree. C. for 24 h. The mixture is then chromatographed over a Sephadex G50 spin column (Pharmacia). A mixture of Taq and E. coli mutS (10 pmol each) is added to 1 .mu.g of the eluted DNA in 50 mM HEPES pH7.2, 7 mM MgCl₂, 1 mM DTT, and the mixture incubated 30 min on ice. The mixture is then digested with 20 units T7 gene 6 exonuclease (Amersham) for 15 min at 37.degree. C. The reaction is quenched by phenol extraction and chromatography over Sephadex G50. Two oligonucleotide adapters having the sequences (1) 5'-HO-GGCCACGGTCCGAAGACCTCNNN-OH-3' and (SEQ ID NO: 6) (2) 5'-HO-GGGCCGGACCGGATGGGATCANNN-OH-3' (SEQ ID NO: 7) are ligated to the DNA digest in 50 mM Tris.HCl, 10 mM MgCl₂, 1 mM ATP and 1 mM DTT with 5 Weiss units T4 DNA ligase at room temperature for 1 hr. To remove overhanging ends left by the T7 exonuclease, 100 units exonuclease I (Amersham) are added, and the mixture incubated for 30 min at 37.degree.. The products are rendered fully double-stranded by incubation with 5 units T4 DNA polymerase, and 200 .mu.M each dATP, dGTP, dCTP, and TTP for 10 min at 37.degree.. The mixture is then heated to inactivate any residual exonuclease, and amplified by PCR utilizing primers identical to the sequences above, except lacking the 3' degenerate nucleotides (Primer Set 1).

Detailed Description Text (94):

A separate parallel experiment is performed with pooled genomic DNA from a control population of individuals suspected of being free of genetic defects in the selected gene, but otherwise being similar to the heterozygous sample by way of national origin, race, or other distinguishing characteristics known to represent a source of variation in the frequency of the disease. In this case, the final amplification is performed with primers (Primer Set 2) which will not crosshybridize with the primers used for the heterozygous DNA. This set of products is biotinylated either by introduction of biotin into the primers or following PCR by tailing with biotinylated deoxynucleoside triphosphates and TdT. The products are hybridized to the products of the heterozygote PCR, and material annealing to the control products is removed by adsorption to streptavidin agarose. After hybridization and chromatography (described above), the samples are incubated with 50 .mu.g streptavidin agarose (Life Technologies, Inc.) for 30 min at room temperature in 1M NaCl, 10 mM Tris, 1 mM EDTA pH7.5. The unbound material is recovered by G50 spin column chromatography. This "subtracted" library is reamplified using primer set 1, and the subtraction and amplification steps performed one additional time. Finally, the products are cloned into appropriate vectors and the products sequenced. This may advantageously be performed by first ligating the sequences into tandem arrays (preferably of 600 nucleotides) allowing high-throughput analysis of the sequences. Mutations are identified by isolation of two alleles differing by only limited sequence changes (transitions, transversions, and deletion/insertions of up to 3 nucleotides). A set of allele-specific oligonucleotides designed to hybridize and distinguish the two alleles can then be utilized to perform segregation analysis in families of affected individuals. The DNA from identified clones is then used to screen cDNA libraries, and may be used to extract genomic DNA fragments, messenger RNA or cDNA prior to cloning and screening.

Detailed Description Paragraph Table (1):

SEQUENCE LISTING <100> GENERAL INFORMATION: <160> NUMBER OF SEQ ID NOS: 7 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 1 <211> LENGTH: 26 <212> TYPE: DNA <213>
ORGANISM: Unknown <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 1
annntgaggc tgcggaccgt gggccn 26 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 2
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Unknown <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 2 ggcccacggt ccgcagcctc a 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 3 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Unknown <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 3 ggcccacggt
ccgcagcctc a 21 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 4 <211> LENGTH: 39
<212> TYPE: DNA <213> ORGANISM: Unknown <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 4 ctcagactcc cagcccaaaa ataaaataac atcctgaat 39 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 5 <211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM:
Unknown <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 5 ctcagactcc
cagcccttac ctgtattttg tttattgct 39 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 6
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Unknown <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 6 ggcccacggt ccgaagacct cnnn 24 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 7 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Unknown <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 7 gggccggacc
ggatgggatc annn 24

Other Reference Publication (1):

Southern, E.M. "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis" J. Mol. Biol. 98:503-517 (1975).

Other Reference Publication (3):

Su, S-S. and Modrich, P. "Escherichia coli mutS-Encoded Protein Binds to Mismatched DNA Base Pairs" PNAS USA 83:5057-5061 (1986).

Other Reference Publication (5):

Yeh et al. "Two Nicking Enzyme Systems Specific for Mismatch-Containing DNA in Nuclear Extracts from Human Cells", J. Biol. Chem. 266(10):6480-6484 (1991).

Other Reference Publication (6):

Lee et al. "p53 and its 14 kDa C-Terminal Domain Recognize Primary DNA Damage in the Form of Insertion/Deletion Mismatches" Cell 81:1013-1020 (1995).

Other Reference Publication (8):

Mashal et al. "Detection of Mutations by Cleavage of DNA Heteroduplexes with Bacteriophage Resolvases" Nature Genetics 9:177-183 (1995).

Other Reference Publication (10):

Miller, R.D. and Riblet, R. "Improved Phenol Emulsion DNA Reassociation Technique (PERT) Using Thermal Cycling" Nucl. Acids Res. 23(12):2339-2340 (1995).

Other Reference Publication (11):

Ellis et al. "MutS Binding Protects Heteroduplex DNA from Exonuclease Digestion In Vitro: A Simple Method for Detecting Mutations" Nucl. Acids. Res. 22(13):2710-11 (1994).

Other Reference Publication (14):

Su, S-S. and Modrich, P. "Escherichia coli mutS-Encoded Protein Binds to Mismatched DNA Base Pairs" PNAS USA 83:5057-61 (1986).

Other Reference Publication (15):

Rees et al. "Betaine Can Eliminate the Base Pair Composition Dependence of DNA Melting" Biochemistry 32:137-44 (1993).

Other Reference Publication (16):

Mayall, E. and Williams, C. "A Method for Routinely Extracting DNA from Buccal Cells for Cystic Fibrosis Carrier Screening" J. Med. Genet. 27:658 (1990).

CLAIMS:

2. The method according to claim 1, wherein step (d) comprises contacting the duplex with an agent having DNA polymerase activity and a mixture of 2 to 3 different deoxynucleoside triphosphates.
6. The method according to claim 5, wherein step (d) comprises contacting the duplexes with an agent having DNA polymerase activity and a mixture of 2 to 3 different deoxynucleoside triphosphates.
10. The method according to claim 9, wherein step (d) comprises contacting the duplex with an agent having DNA polymerase activity and a mixture of 2 to 3 different deoxynucleoside triphosphates.
13. The method according to claim 12, wherein step (d) comprises contacting the duplex with an agent having DNA polymerase activity and a mixture of 2 to 3 different deoxynucleoside triphosphates.